Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom
Depo-Medrone 40 mg/ml.
| Pharmaceutical Form |
|---|
|
Suspension for Injection. White, sterile, white aqueous suspension. |
Methylprednisolone acetate 40 mg/ml.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Methylprednisolone |
Methylprednisolone is a synthetic glucocorticoid and a methyl derivative of prednisolone. Methylprednisolone is a potent anti-inflammatory agent with the capacity to profoundly inhibit the immune system. |
| List of Excipients |
|---|
|
Polyethylene glycol |
Type I flint glass vial with a butyl rubber plug and metal seal. Each vial contains 1 ml, 2 ml, or 3 ml of Depo-Medrone 40 mg/ml.
Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom
PL 00057/0963
Date of first authorisation: 7 March 1989
Date of latest renewal: 5 September 1996
| Drug | Countries | |
|---|---|---|
| DEPO-MEDRONE | Ireland, Malta, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
